Thermo Fisher Scientific Inc. TMO recently announced the receipt of the FDA premarket approval (PMA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify epidermal growth ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results